Pinetree invests in Manitex Capital

Pinetree Capital has made a continued investment in Manitex Capital, of which it now owns a 17 percent interest. Montreal-based Manitex specializes in acquiring interests in emerging companies, including those supplying materials and finished products to the pharmaceutical industry. The company recently sold several specialty product assets of its portfolio company Valeo Pharma to Valeant Pharmaceuticals for $25.3 million.


Pinetree Capital Ltd. Acquires Securities of Manitex Capital Inc.

TORONTO, CANADA–(Marketwired – Aug. 29, 2014) – Pinetree Capital Ltd. (PNP.TO), announces that on August 28, 2014, it acquired ownership of 22,500 common shares (“Common Shares”) of Manitex Capital Inc. (“Manitex”) through the facilities of the TSX Venture Exchange, representing approximately 0.2% of the total issued and outstanding common shares of Manitex as of August 28, 2014. As a result of this transaction, Pinetree and its joint actors collectively held, as at August 28, 2014, an aggregate of 2,277,406 common shares of Manitex, including the Common Shares, or approximately 18.4% of the total issued and outstanding common shares of Manitex as of August 28, 2014. Of these totals, Pinetree owns 2,122,406 common shares, including the Common Shares, directly, or approximately 17.2% of the total issued and outstanding common shares of Manitex as of August 28, 2014.

These transactions were made for investment purposes and Pinetree and its joint actors could increase or decrease their investment in Manitex depending on market conditions or any other relevant factor.

About Pinetree

Pinetree Capital Ltd. (“Pinetree”) was incorporated under the laws of the Province of Ontario and its shares are publicly-traded on the Toronto Stock Exchange (“TSX”) under the symbol “PNP”. Pinetree is a diversified investment and merchant banking firm focused on the small cap market. Pinetree’s investments are primarily in the following sectors: Precious Metals, Uranium and Technology. Pinetree’s investment approach is to develop a macro view of a sector, build a position consistent with the view by identifying micro-cap opportunities within that sector, and devise an exit strategy designed to maximize our relative return in light of changing fundamentals and opportunities. Pinetree is recognized as a value added partner.


Pinetree Capital Ltd.
Sheldon Inwentash, CPA, CA.
Chairman & CEO

Pinetree Capital Ltd.
Gerry Feldman, CPA, CA.
CFO & Vice President, Corporate Development

Investor Relations:
Pinetree Capital Ltd.
Richard Patricio, LL.B.
Vice President, Legal and Corporate Affairs
416-941-9600 /

Photo courtesy of Shutterstock.